Commentary
Volume 18:1, 2026

Cancer Science & Therapy

ISSN: 1948-5956 Open Access

Functional Immune Biomarker Identification in Patients with Breast Cancer

Robert Jocelyn*

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, USA

Description

Breast Cancer (BC) remains one of the most prevalent and deadly forms of cancer among women worldwide. Despite significant advancements in early detection, treatment modalities, and understanding of its molecular mechanisms, breast cancer continues to pose a substantial challenge to global health. One of the promising areas in cancer research is the study of the immune system's interaction with tumor cells. The immune system plays a critical role in both preventing and promoting tumorigenesis, and understanding its dynamics in cancer patients has led to the identification of immune biomarkers that can guide therapeutic interventions. In particular, functional immune biomarkers in breast cancer have become a central focus of research due to their potential to predict disease progression, response to treatment, and patient prognosis. This paper delves into the identification and implications of functional immune biomarkers in patients with breast cancer, discussing their role in the Tumor Microenvironment (TME), their impact on patient management, and their potential in future therapeutic strategies.

The immune system is composed of various cell types, including T cells, B cells, Natural Killer (NK) cells, Dendritic Cells (DCs), and macrophages, that work in concert to recognize and destroy abnormal or foreign entities. In the context of cancer, the immune system is tasked with identifying and eliminating transformed cells that could develop into malignancies. However, cancer cells can evade immune surveillance by exploiting various mechanisms, including the expression of immune checkpoint molecules, secretion of immunosuppressive cytokines, and alteration of immune cell infiltration patterns in the Tumor Microenvironment (TME).

In recent years, there has been growing interest in the identification of immune biomarkers that reflect the functional state of the immune system within the TME, as these biomarkers can provide insights into the immunological landscape of breast cancer and offer prognostic or predictive value.

Functional immune biomarkers are measurable indicators that reflect the immune system's activity and its ability to respond to or interact with the tumor. Unlike conventional biomarkers, which primarily indicate tumor burden or tissue damage, functional immune biomarkers provide a deeper understanding of the immune response to the tumor and the potential for therapeutic intervention. These biomarkers can be classified based on their role in immune surveillance, immune evasion, or immune activation.

Additionally, functional immune biomarkers are not limited to just immune cells but may also include components of the TME, such as Extracellular Vesicles (EVs), which have been shown to carry immunologically relevant molecules that reflect the functional state of both tumor and immune cells. These biomarkers are highly valuable in monitoring disease progression, predicting treatment responses, and evaluating therapeutic efficacy, especially in the context of immunotherapies. Several functional immune biomarkers have been identified in breast cancer patients, with particular focus on immune checkpoint molecules, immune cell populations, cytokines, and soluble factors in the TME.

Tumor-Infiltrating Lymphocytes (TILs) are immune cells that migrate into the tumor tissue as part of the body's immune response to cancer. TILs include various types of immune cells, such as T cells, B cells, and NK cells. The presence of TILs in breast cancer is associated with a favorable prognosis and better responses to certain therapies, including chemotherapy and immunotherapy. High levels of TILs are particularly important in TNBC, which tends to have a higher immune cell infiltration compared to other subtypes of breast cancer.

The functional state of TILs can also provide important insights into the immune response within the TME. For example, TILs that are exhausted, as indicated by high expression of PD-1 or other markers of immune exhaustion, may be less effective in combating the tumor.

***Address for Correspondence:** Robert Jocelyn, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, USA; E-mail: rjocelyn@gmail.com*

Received: 26 November 2024, Manuscript No. JCST-24-153325; **Editor assigned:** 29 November, 2024, PreQC No. JCST-24-153325 (PQ); **Reviewed:** 12 December, 2024, QC No. JCST-24-153325; **Revised:** 14 February, 2026, Manuscript No. JCST-24-153325 (R); **Published:** 21 February, 2026, DOI: 10.37421/1948-5956.2026.18.685

Conversely, activated TILs are often associated with a better prognosis and improved response to immune-based therapies. In addition to cytokines, soluble factors such as exosomes and other Extracellular Vehicles (EVs) can serve as biomarkers reflecting the functional immune state of breast cancer. These vesicles carry a wide range of molecules, including proteins, lipids, and nucleic acids, that can influence immune cell behavior. By analyzing the content of EVs in plasma or tumor samples, researchers can gain insights into the tumor-immune interactions that drive cancer progression and therapeutic response.

Natural Killer (NK) cells are a critical component of the innate immune response and play a role in detecting and killing tumor cells. NK cells can recognize tumor cells without prior sensitization and are involved in the early stages of immune surveillance. In breast cancer, the activity and frequency of NK cells have been associated with improved prognosis, and lower NK cell activity is often linked to tumor progression.

The functional status of NK cells can be assessed through the expression of activating receptors such as *NKG2D* and the ability to release cytotoxic molecules like perforin and granzyme. Dysfunctional NK cells within the TME may limit the anti-tumor immune response, and therapies that enhance NK cell activity are being explored in clinical trials.

Functional immune biomarkers are increasingly being recognized for their role in predicting prognosis and guiding treatment decisions in breast cancer. Several immune-related features, such as the composition of TILs, the expression of immune checkpoints, and the presence of immune-modulatory cytokines, are used in clinical practice to evaluate the likelihood of response to therapy and overall survival outcomes. The success of immunotherapies, such as immune checkpoint inhibitors, in breast cancer patients largely depends on the tumor's ability to elicit an immune response. Immune biomarkers can help identify patients who are most likely to benefit from these therapies. For instance, high PD-L1 expression is often correlated with better responses to PD-1/PD-L1 inhibitors in breast cancer, although additional biomarkers are needed to refine patient selection. Similarly, the abundance of TILs and the presence of immune-exhausted T cells can also provide valuable information on the immune landscape of the tumor and the likelihood of a successful response to immunotherapy.

The identification of functional immune biomarkers allows for more personalized treatment strategies. For example, a patient with high levels of immunosuppressive Tregs might benefit from therapies aimed at depleting or inhibiting Tregs, while a patient with active TILs might benefit from strategies to enhance the anti-tumor immune response. Similarly, monitoring changes in immune biomarkers during treatment can provide valuable feedback on treatment efficacy and help guide decisions on whether to continue or adjust the therapeutic regimen.

The identification of functional immune biomarkers in breast cancer patients has the potential to revolutionize the way we approach cancer diagnosis, treatment, and monitoring. These biomarkers provide critical insights into the dynamic interactions between the tumor and the immune system, and their identification can guide clinical decisions in both early-stage and metastatic disease. As research in this field advances, it is likely that we will see an increasing integration of functional immune biomarkers into clinical practice, ultimately leading to more effective and personalized therapies for breast cancer patients.

How to cite this article: Jocelyn, Robert. "Functional Immune Biomarker Identification in Patients with Breast Cancer." *J Cancer Sci Ther* 18 (2026): 685.